HiRO - Harvest Integrated Research Organization

HiRO - Harvest Integrated Research Organization is positioning itself as a dynamic player in the realm of clinical research, with its strategy centered around the slogan: Streamline & Accelerate Cross-border Clinical Trial Pathways. Founded in 2020 and headquartered in the United States, HiRO seeks to provide an expansive portfolio of services designed to address the complexities of conducting clinical research across borders. Their offerings encompass everything from early-stage strategic planning through to end-to-end project management, reflecting a comprehensive approach tailored to meet the needs of the Biopharma, Biotechnology, and Pharmaceutical industries.

The company's ambition is supported by a significant Series A investment of CNY10.00M received on 18 March 2022, spearheaded by prominent venture entities such as New Alliance Capital, OrbiMed, FC Capital, and Panacea Venture. These investments underscore confidence in HiRO's potential to innovate and navigate the nuanced terrains of global clinical trials effectively, positioning it for future growth in a competitive market.